A novel study in the Journal of Investigative Dermatology, shows that patients with vitiligo incur significantly higher health care costs than people without this skin condition. The findings reveal an unmet need for cost-effective ...
Jan 31, 2024
0
1
Transplant recipients, especially those receiving hematopoietic stem cell transplant (HSCT), have an increased risk for vitiligo, according to a brief report published online Dec. 13 in JAMA Dermatology.
Dec 21, 2023
0
0
A high proportion of patients with newly diagnosed vitiligo do not receive any treatment, according to a study recently published in Dermatology and Therapy.
Oct 17, 2023
0
0
Patients with vitiligo may have a reduced risk for mortality, according to a study published online Sept. 14 in the Journal of Investigative Dermatology.
Oct 1, 2023
0
1
According to a new study comparing patients with and without vitiligo in South Korea, patients with vitiligo were associated with a 25% decreased risk of mortality compared with controls. This suggests that vitiligo-associated ...
Sep 19, 2023
0
7
Vitiligo diagnosis is more common in older adults and in Hispanic/Latino and Asian American patients, according to a study published online July 19 in JAMA Dermatology.
Jul 24, 2023
0
5
For patients with nonsegmental vitiligo, continued improvement in seen during a long-term extension of ruxolitinib treatment, according to study presented at the annual meeting of the American Academy of Dermatology, held ...
Mar 28, 2023
0
5
Sarah Hayden owns a lot of turtlenecks. She also has chunky necklaces and tons of makeup—anything to cover up the blotchy white skin on her face, neck, hands and knees.
Oct 21, 2022
0
2
For patients with vitiligo, ruxolitinib cream results in greater repigmentation of lesions compared with vehicle control, according to a study published online Oct. 20 in the New England Journal of Medicine.
Oct 20, 2022
0
5
The U.S. Food and Drug Administration has approved Opzelura (ruxolitinib) as the first topical treatment for vitiligo.
Jul 21, 2022
0
31
Vitiligo ( /ˌvɪtɨˈlaɪɡoʊ/) is a condition that causes depigmentation of sections of skin. It occurs when melanocytes, the cells responsible for skin pigmentation, die or are unable to function. The cause of vitiligo is unknown, but research suggests that it may arise from autoimmune, genetic, oxidative stress, neural, or viral causes. The incidence worldwide is less than 1%. The most common form is non-segmental vitiligo, which tends to appear in symmetric patches, sometimes over large areas of the body.
This text uses material from Wikipedia licensed under CC BY-SA
